First human test of novel drug aims to tame rogue immune cells in lupus and arthritis
NCT ID NCT07371468
Summary
This is a first-in-human study to test the safety and tolerability of a new investigational drug called GSK5926371. It is designed for adults with autoimmune rheumatic diseases like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The main goal is to find a safe dose and see how the body handles the drug, which works by engaging the immune system to target specific B-cells thought to drive these diseases.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
GSK Investigational Site
Hokkaido, 060-8648, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.